All News

Tom Scully, administrator of the Centers for Medicare & Medicaid Services, will resign effective Dec. 15, following 3 years at the helm of two of the nation's largest domestic programs.

The FDA has approved what is said to be the first gonadotropin releasing hormone (GnRH) antagonist for prostate cancer available as a depot formulation. Abarelix (Plenaxis) is indicated for the palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate, who refuse surgical castration, and have one or more of the following: risk of neurologic compromise due to metastases; ureteral or bladder outlet obstruction due to local encroachment or metastatic disease; or severe bone pain from skeletal metastases persisting on narcotic analgesia.

In this month's issue of Urology Times, attention is given to evolvingmethods for treating renal masses in less invasive ways, including laparoscopicnephron-sparing surgery and cryosurgical ablation.

Portland, OR-Weekly preoperative chemotherapy with docetaxel (Taxotere)and mitoxantrone (Novantrone) reduced PSA levels and was associated witha high rate of negative surgical margins in a small preliminary clinicaltrial involving high-risk localized prostate cancer patients.

Report calls for more study of testosterone replacement; urologists saybenefits are knownWashington-Clinical studies on the use of testosterone replacementtherapy (TRT) in men over age 65 years should move forward to determinethe efficacy of testosterone therapy in older men and the nature and extentof the potential benefits, according to a report released last month byan expert committee of the Institute of Medicine (IOM). Initially, studiesshould include a limited number of participants and proceed in a stepwisefashion, the report said.

Jackson, MS-Magnetic resonance imaging offers a far better picture of both tumors and a growing ice ball, and these factors may contribute to the success seen in the University of Mississippi's percutaneous cryoablation procedure in treating renal cell carcinoma, according to W. Bruce Shingleton, MD, formerly at the University of Mississippi and currently associate professor of surgery and radiology, division of urologic surgery, University of Louisville (KY) School of Medicine.

Cleveland-Immunoscintigraphy scanning, criticized in the past for poor performance in imaging metastatic disease, may have found a reliable niche in the treatment of prostate cancer.

Chicago-Although laparoscopic nephron-sparing surgery is a firmly established procedure, its full potential has not yet been reached, according to a host of studies intended to demonstrate the expanding range of the procedure's applications.

Prostate cancer patients who receive hormone treatments before undergoing three-dimensional conformal radiation therapy (3D-CRT) do not have increased side effects compared with those not receiving hormone therapy before radiation, according to a new study in the International Journal of Radiation Oncology, Biology Physics (2003; 57: 614-20).

A treatment approach that uses a donor's immune cells appears to provide anti-cancer activity in some patients with recurrent or refractory renal cell carcinoma, according to research published in the Journal of Clinical Oncology (2003; 21: 3785-91).

The percentage of American men with early prostate cancer who were treated with brachytherapy increased from less than 5% in 1994 to 36% in 1999, according to a report published in Cancer (2003; 98: 1987-94).

Santa Monica, CA?Patients aged 65 years and older with urinary incontinence and other health problems affecting their independence fail to receive recommended medical care for these conditions about two-thirds of the time, according to a study by RAND Corp. and UCLA.

San Jose, CA?The Centers for Medicare and Medicaid Services has approved an application for assigning a new technology Ambulatory Payment Classification for photoselective vaporization of the prostate (PVP) to treat BPH.

Chicago-Large-scale telephone-based management of eligible women withpresumed cystitis is associated with low clinical recurrence rates and avery low incidence of other gynecourologic diagnoses, according to a studyfrom a large California health maintenance organization.

Paris-Basic research in erectile dysfunction therapy is being hamperedby the attitude of some funding bodies that phosphodiesterase type-5 inhibitorsalone have solved all problems, according to a special committee convenedat the 2nd International Consultation on Erectile and Sexual Dysfunctionshere.